Clara Rodríguez Fernández, Author at Labiotech.eu

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

News and Trends 4 Jan 2017

Cold Sore Cure Company enters the Antibiotic Resistance fight

AiCuris is developing a new antibiotic that might bring hope for patients in which all options to fight infections have been exhausted. AiCuris, a German company leading the fight against infectious diseases, is now entering clinical trials with a new antibiotic. The candidate, AIC499, is a β-lactam effective against a broad range of Gram-negative multi-drug resistant […]

January 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Jan 2017

This British Biotech is buying its way into the Crowded NASH Space

Tiziana Life Sciences is acquiring candidates to gain leverage in the profitable NASH market, where there’s currently a fierce competition. Tiziana Life Sciences, a biopharmaceutical company from London, is planning to enter the competitive space of non-alcoholic steatohepatitis (NASH). To gain leverage over bigger companies fighting to enter a market expected to hit a massive €38B ($40B) by […]

January 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 3 Jan 2017

Bacteria can Protect each other: a New Challenge in Antibiotic Resistance

Researchers have discovered a new mechanism by which antibiotic-resistant bacteria can protect non-resistant pathogens. What are the implications? Scientists have described a new strategy that pathogens use to survive our efforts to eliminate them: resistant bacteria can inactivate antibiotics and allow their neighbor pathogens to grow once the active compound has reached low enough levels. The […]

January 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 3 Jan 2017

New German Immuno-oncology Partnership takes on Solid Tumors

TCR2 Therapeutics is initiating a partnership with academia to boost its TCR technology with the aim of overcoming the huge challenges of treating solid tumors. TCR2 Therapeutics, a Boston immuno-oncology startup launched in 2015 and funded by the Munich biotech mafia, is starting the year with a multi-year collaboration with the University Hospital of Ludwig-Maximilians-University (LMU) in, […]

January 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Jan 2017

An EU Project will tackle Multiple Sclerosis using Personalized Multi Omics

The MultipleMS Consortium has been granted €15M by the EU Horizon 2020 to improve the treatment of multiple sclerosis using personalized medicine. The EU Horizon 2020 has kicked off the year with a project to develop, validate, and exploit methods for the personalized treatment of multiple sclerosis (MS). The 21 institutions from 12 European countries and […]

January 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Jan 2017

Fresh Cash for a Device that Can Treat Diabetes and Prevent HIV

Intarcia will develop a drug delivery device for HIV prevention that can significantly reduce dosing frequency, backed by a €134M ($140M) deal with the Bill & Melinda Gates Foundation. Intarcia is a biotech unicorn from the US with an innovative drug delivery system that has managed to attract €197M ($206M) in Series EE, including €48M ($50M) from […]

January 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 12 23 at 6.26.13 PM e1482514040545

News and Trends 28 Dec 2016

Discussing the Future of Personalized Medicine with Biotech Experts

Personalized medicine has been a popular topic in the last few years, but when will it materialize? Experts discussed the current challenges at Labiotech Refresh. Jean-Pol Detiffe is the CEO of OncoDNA, a company using next-generation sequencing to match patients with a personalized cancer treatment. In his opinion, one of the main challenges in the […]

December 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 12 23 at 10.15.37 AM e1482485076955

News and Trends 27 Dec 2016

This SynBio Start-up is Redefining the Rules of Evolution

Biosyntia wants to reduce time and expenses in vitamin production by engineering microorganisms. Watch Hans Genee pitch his company at Labiotech Refresh! Many chemicals are currently produced using chemical synthesis. Hans Genee wants to be a “driver of the transition towards biobased products“. His strategy is to “redefine evolution rules to reduce cost and time” in […]

December 27, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 26 Dec 2016

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

Curious about which technologies have attracted the most cash in biotech finance this year? Here’s a list of the most impressive cash movements of 2016 in Europe. Believe it or not, 2016 has been the worst year for biotech finance in a decade. The political scene has become unfavorable for British biotech after Brexit, and the uncertainty raised by […]

December 26, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 12 20 at 6.10.44 PM e1482253923994

News and Trends 24 Dec 2016

Do Try this at Home: Growing Bacterial Paper with Open-source Bioart

The work of Diane Trouillet uses living organisms to create open-source bioart that everyone can try to replicate at home. Diane Trouillet, a self-proclaimed artist-researcher from Toulouse, is moving the French art community. Back in 2013, the bioartist invented a bacterial paper that she is now exploring as an artistic medium. Her most recent project, […]

December 24, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Dec 2016

The 8 Biggest Biotech Medical Fails of 2016 in Europe

Although 2016 has brought plenty of good news in medical advances, biotech is an industry where failure is part of the game. Here’s a list of medical fails in biotech to learn from this year. Unfortunately, 2016 has not been a good year for pharma, with revenues in the top companies falling, the lowest number […]

December 23, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Dec 2016

BMS Offers €850M for a British Oncolytic Virus better than CAR-T

BMS is offering PsiOxus Therapeutics a massive deal to get exclusive rights of an oncolytic virus that could outperform the promising CAR-T therapies. PsiOxus Therapeutics, based in Oxford, develops immuno-oncolytic viruses to treat solid tumors. Its technology attracted a partnership with Bristol-Myers Squibb earlier this year, which is now offering the British biotech an impressive €850M […]

December 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Clara Rodríguez Fernández

About

Articles by Clara Rodríguez Fernández

Cold Sore Cure Company enters the Antibiotic Resistance fight

This British Biotech is buying its way into the Crowded NASH Space

Bacteria can Protect each other: a New Challenge in Antibiotic Resistance

New German Immuno-oncology Partnership takes on Solid Tumors

An EU Project will tackle Multiple Sclerosis using Personalized Multi Omics

Fresh Cash for a Device that Can Treat Diabetes and Prevent HIV

Discussing the Future of Personalized Medicine with Biotech Experts

This SynBio Start-up is Redefining the Rules of Evolution

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

Do Try this at Home: Growing Bacterial Paper with Open-source Bioart

The 8 Biggest Biotech Medical Fails of 2016 in Europe

BMS Offers €850M for a British Oncolytic Virus better than CAR-T

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Clara Rodríguez Fernández

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!